It is my privilege to introduce the IASLC Lung Cancer News (ILCN). I will be serving as Editor with the able assistance of my Associate Editors, Fabrice Barlesi, MD from Europe and Caicun Zhou, MD from Asia. ILCN is a new tabloid publication that will highlight updates on thoracic malignancy research, including diagnostics, screening, tobacco control, therapeutic interventions, quality of life, symptom management, and survivorship. This tabloid will acknowledge the complex interplay that exists between these investigational realms and between all stakeholders in the research and care of individuals with thoracic cancers, and will feature expert commentary from thoracic oncology leaders, industry, and regulators. The target audience for this publication encompasses researchers, physicians, and other specialists, including allied health professionals, involved in the care of patients with thoracic malignancy.
ILCN is structured to present the most recent and noteworthy lung cancer-related information worldwide; in addition, themed issues will be planned around particular topics or meetings, and we will not shy away from ongoing controversies and debates. We have twin goals of facilitating professional development and improving patient care and research, and ultimately clinical outcome. Year 1 of the publication will consist of 1 issue each quarter, 16 pages each, and will be distributed in print and electronically to US and international thoracic cancer specialists. During year 2, we plan to transition to an issue every two months, with up to 32 pages each.
Each issue will include, but will not be limited to, the following topics:
• Meeting Highlights and Previews
• Expert Corner
• NCI Corner
• FDA Corner
• Global Research Spotlights
• Recent International Drug Approvals
• Lung Cancer Screening
• Tobacco Control and Smoking Cessation
• Navigating Therapeutic Controversy
• Managing Toxicities and Patient Expectations
• Survivorship Perspectives
• Lung Cancer in the Media
• Names in the News
Our intention is to accomplish the following:
• Signal our evolving understanding of tobacco control and lung cancer screening
• Underscore current debates and controversies in the interdisciplinary management of patients with lung cancer
• Summarize recent advances and innovations in genomic sequencing and target therapies
• Expand our working knowledge of immunotherapeutics in thoracic malignancy
• Describe reported advances in basic and translational sciences by lung cancer researchers
• Highlight the activities and impact of lung cancer leaders and advocates in the care of patients with lung cancer
On behalf of my Associate Editors and Deborah Whippen, Managing Editor and Publisher, I welcome your attention, your input, and suggestions.